176 related articles for article (PubMed ID: 36170799)
1. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
[TBL] [Abstract][Full Text] [Related]
2. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
3. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
[TBL] [Abstract][Full Text] [Related]
4. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
5. Ensemble docking-based virtual screening toward identifying inhibitors against Wee1 kinase.
Li Y; Wu DM; Kong LM; Zhang S; Du H; Sun W; Zhang L; Li Y; Zuo Z
Future Med Chem; 2019 Aug; 11(15):1889-1906. PubMed ID: 31517534
[No Abstract] [Full Text] [Related]
6. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
7. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
Matheson CJ; Casalvieri KA; Backos DS; Reigan P
ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
[TBL] [Abstract][Full Text] [Related]
8. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
9. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors.
Ye Q; Ma J; Wang P; Wang C; Sun M; Zhou Y; Li J; Liu T
Bioorg Med Chem; 2023 May; 87():117312. PubMed ID: 37167712
[TBL] [Abstract][Full Text] [Related]
11. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
13. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
16. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
Sand A; Piacsek M; Donohoe DL; Duffin AT; Riddell GT; Sun C; Tang M; Rovin RA; Tjoe JA; Yin J
Cancer Lett; 2020 Mar; 472():119-131. PubMed ID: 31866466
[TBL] [Abstract][Full Text] [Related]
17. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
Wang B; Sun L; Yuan Z; Tao Z
Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
[TBL] [Abstract][Full Text] [Related]
18. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
